GSK: UBS downgrades stock

(CercleFinance.com) - UBS has downgraded GlaxoSmithKline (GSK) shares to "sell" (from "neutral"), having reduced its target price for them to 1,300 pence (from 1,820 pence), as the broker said it sees "uncertain times ahead" for the British pharmaceutical company.


"As Shingrix will exhaust its US patient pool at a similar time as dolutegravir loses its patent protection, a big part of GSK's earnings could be at risk," it warns in its summary.

The market agrees, with the share down 5% this morning.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.